samedan logo
 
 
spacer
home > epc > winter 2002 > the ethics of research related to health care in developing countries - implications of the report for the pharmaceutical industry
PUBLICATIONS
European Pharmaceutical Contractor

The Ethics of Research Related to Health Care in Developing Countries - Implications of the Report for the Pharmaceutical Industry

Medical research in developing countries that is funded by organisations in wealthy countries is crucial, but it must be subject to rigorous ethical safeguards, according to a recently published report by the Nuffield Council on Bioethics. While acknowledging that some externally-funded research has been controversial in the past, the report, The Ethics of Research Related to Healthcare in Developing Countries, highlights the need to continue to support future research, provided it is appropriately planned and effectively reviewed on scientific and ethical grounds. The report is the outcome of two years of consultation by an international working party, which included experts from the fields of medicine, health care, anthropology, philosophy and public policy.

The Nuffield Council on Bioethics set up the working party in 2000, partly in response to the international controversies surrounding HIV research in Thailand and Africa. Additionally, there has recently been a significant increase in health care research in developing countries, supported by a variety of different sponsors. Sponsors range from multinational pharmaceutical companies and voluntary organisations to governments and international bodies such as the World Health Organization (WHO). While some forms of sponsorship have been altruistic, others have been driven by academic interests or by economic considerations. These interests do not necessarily reflect national priorities for research in the country in which the research is to be conducted.

Developing countries urgently need research to help relieve the enormous burden of disease they carry, including diseases such as TB and malaria. But many countries have limited funds and a lack of trained staff to conduct their own research. Each year £35-40 billion is spent on health care research worldwide but only 10 per cent of this is devoted to the health problems of 90 per cent of the world's population. It is vital that both the public and private sectors in developed countries sponsor research to help bridge the gap.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Sir Kenneth Calman, Vice-Chancellor and Warden at the University of Durham

Professor Sir Kenneth Calman KCB FRSE is Vice-Chancellor and Warden of the University of Durham. He trained in surgery and became Professor of Oncology at the University of Glasgow.

Formerly CMO for Scotland and subsequently England, he is also Chairman of the WHO Executive Board. He is a member of the Nuffield Council on Bioethics and chaired the Working Party on the ethics of research related to health care in developing countries.


spacer
Professor Sir Kenneth Calman
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Inaugural Conference on Pre-Filled Syringes

21-22 January 2009, Crowne Plaza Hotel - St James, London, UK

SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >>

 
News and Press Releases

Aegate Proves Authenticating Drugs at the Point of Dispensing Protects Consumers

 
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement